Topic Listing for Sunesis Pharmaceuticals

Accounting Certain Transactions Involving Stock Compensation Interpretation Apb Accounting Firm
Accounting Pronouncements Affect Future Financial Position Results Operations Accounting Stock Issued Employees
Accounting Stock-based Compensation Accounting Treatment
Accounts Payable Other Accrued Liabilities Action Committee
Actual Participation Acute Myeloid Leukemia
Addendum Office Lease Adea
Adea Waiver Adjustment Bonus Targets Based Level Achievement Corporate Objectives
Adjustment Common Stock Dividends Distributions Adjustment Exercise Price Shares
Adjustment Reclassification Exchange Substitution Adjustment Stock Splits Combinations
Adjustments Adjustments Other Dividends Distributions
Administration Advice
Affiliate Aggregate Common Equity Closing Subscription Amount
Agreement Agreement Payments
Alternative Common Stock Financing Amended Restated Executive Severance Benefits Agreement
Amendment Modification Termination Amendment Rent
Amendment Termination Agreement Amendment Waiver
Annual Bonus Annual Meeting Attendance
Annual Report Form 10-k Available Information Anthony Evnin Phd
Anthony Evnin Phd Matthew Fust Steven Goldby Jonathan Anti-cancer Program
Anti-viral Inhibitors Program Applicable Portion
Approach Developing Cancer Therapeutics Inhibiting Cdks Aurora Kinases Approach Developing Cancer Therapeutics Inhibiting Cyclin-dependent Kinases Aurora
Arbitration Ash Presentations
Asis Ayments Rom Lan Assigned Patents
Assignment Attestation Report Registered Public Accounting Firm
Attorneys Fees Audit Committee
Audit Committee Report Audit Fees
Audit-related Fees Authority
Authority Committee Available Information
Award Award Agreement
Awards Previously Granted Bace Inhibitors Alzheimers Disease
Base Additional Rent Base Salary
Base Salary Other Benefits Acceleration Basis Presentation
Because Mechanism Action Sns-595 Not Fully Known Choose Benchmarking
Beneficial Ownership Reporting Compliance Beneficiaries
Benefits Change Control Best Pay Provision
Binding Effect Biogen Idec Formerly Inc -tnf Family Oncology Research
Biogen Idec Formerly Inc Tnf Family Oncology Research Biogen Idec Inc
Biogen Idec Inc Related Party Biogen Idec Inc-related Party
Biogen Idec Kinase Research Development Commercialization Collaboration Biogen Idec-kinase Research Development Commercialization Collaboration
Biogen Idec-raf Kinase Other Inhibitors Biographies Executive Officers
Bloomberg Board
Board Directors Board Directors Committees
Board Directors Contingency Board Directors Recommends Vote Director Nominees Nominated Proposal
Board Directors Stockholders Sunesis Pharmaceuticals Inc Board Recommendation
Bonus Bristol-myers Squibb
Brokerage Fee Business
Business Overview Business Taxes
California Courts Cannot Take Fundamental Actions Related Sunesis Without Consent
Capital Stock Cash
Cash Balance Notice Cash Equivalents Marketable Securities
Cash Flow Cash Flows
Cathepsin Inhibitors Program Inflammatory Diseases Cause
Certain Information Respect Executive Officers Key Employees Certain Related Party Transactions
Certain Relationships Related Party Transactions Certain Relationships Related Transactions Director Independence
Certificate Adjustment Certificate Designation
Certificates Restricted Stock Certification Chief Executive Officer
Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act Certification Chief Executive Officer Pursuant 906 Sarbanes-oxley Act
Certification Chief Financial Officer Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Act
Certification Chief Financial Officer Pursuant 906 Sarbanes-oxley Act Change Control
Change Control Equity Incentive Plan Protections Change Control Option Acceleration
Change Control Severance Change Control Severance Benefits
Change Control Severance Protections Change Recommendation
Changes Capital Structure Changes Financial Accounting Standards Related Share-based Payments Expected
Changes Internal Control Over Financial Reporting Changes Stock Option Accounting Rules Adversely Impact Operating
Choice Law Claims
Class Directors Whose Terms Expire 2008 Class Directors Whose Terms Expire 2009
Class Directors Whose Terms Expire 2010 Class Nominees Election Board Directors Three-year Term Expiring
Clinical Trial Accounting Clinical Trials
Clinical Trials Accounting Clinical Trials Lead Product Candidates Sns-595 Sns-032 Sns-314
Closing Closing Bid Price
Closing Milestone Closing Private Placement Resulted Result Further Substantial Dilution
Closing Units Cobra
Code Code 409a
Code Conduct Collaboration Revenue
Commencement Duration Commercial Sublease Agreement
Commitments Commitments Contingencies
Committee Common Equity Closing
Common Equity Closing Date Common Equity Closing Notice
Common Equity Closing Subscription Amount Common Equity Shares
Common Per Share Purchase Price Common Stock
Common Stock Equivalents Common Stock Financing
Common Stock Warrant Purchase Agreement Company8217s Knowledge
Compensation Benchmarking Peer Group Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Process
Compensation Committee Report Compensation Named Executive
Compensation Objectives Compensation Philosophy
Competing Transaction Competition
Competitors Develop Market Products Effective Safer Less Expensive Complete Agreement
Compliance 409a Compliance Act Disposition Warrant Shares Common Stock
Compliance Changing Regulation Corporate Governance Public Disclosure Result Compliance Exchange Act
Composition Matter Patents Covering Sns-032 Due Expire 2018 Composition Matter Patents Covering Sns-314 Due Expire 2025
Composition Matter Patents Covering Sns-595 Due Expire 2015 Composition Matter Patents Covering Voreloxin Due Expire 2015
Comprehensive Income Loss Comprehensive Loss
Concentrations Credit Risk Financial Instruments Conclusion Regarding Effectiveness Disclosure Controls Procedures
Condition Generator Area Surrounding Condition Premises
Conditions Affecting Equity Market Make Difficult Costly Raise Conference Call Information
Conference Call Scheduled Today Monday 100 Discuss Asco Confidential Information
Confidential Information Invention Assignment Agreement Confidentiality
Confidentiality Agreement Confidentiality Terms
Confirmatory Documentation Conflicts
Conflicts Interest Arise Between Collaboration Partners Them Act Consent Independent Registered Public Accounting Firm
Consideration Construction Agreement
Constructive Termination Constructive Termination Option Acceleration
Consulting Agreements Contingencies
Continuing Right Re-offer Priority Continuing Validity Lease
Contractual Obligations Control
Control Defense Controlling
Controls Procedures Conversion Shares
Convertibility Date Cooperation Assistance
Copies Copy
Corporate Event Corporate Governance Guidelines
Corporate Strategy Corporation
Cost Operation Counterparts
Coupled Stock Appreciation Rights Covenants Exercise Shares
Coverage Reimbursement Status Newly Approved Drugs Uncertain Failure Covered Employee
Covered Termination Covered Termination Option Acceleration
Credit Loan Arrangements Critical Accounting Policies Estimates
Critical Accounting Policies Significant Judgments Estimates Csar
Currently Limited Marketing Staff Sales Distribution Organization Unable Currently Sales Marketing Staff Distribution Organization Unable Develop
Dainippon Sumitomo Pharma Dainippon Sumitomo Pharma Ltd
Daniel Adelman Daniel Swisher
Daryl Winter Phd Date Original
David Stump Debt Facility
Default Master Landlord Default Subtenant
Default Termination Defined Contribution Plans
Definitions Delaware Limited Partnership
Delayed Initial Payment Date Deliverables
Delivery Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Depend Various Consultants Advisors Success Continuation Development Efforts
Depend Various Scientific Consultants Advisors Success Continuation Research Determination Bonus Payments Individual Participants
Determination Cash Bonus Payments Determination Compensation Awards
Determination Level Achievement Corporate Objectives Determination Program Objectives
Determinations Development Voreloxin Halted Significantly Delayed Various Reasons Clinical
Director Evaluations Director Nominations Process
Directors Executive Officers Corporate Governance Disability
Disclaimer Disclosure
Disclosure Controls Procedures Disclosure List
Disclosure Materials Distributed Property
Dividend Equivalents Dividend Policy
Dividend Rights Documents Incorporated Reference
Dtc Duplication
Duplication Benefits Each Party Hereby Acknowledges Provision Material Inducement Agent
Early Occupancy Ecitals
Economic Conditions Make Difficult Costly Raise Additional Capital Effect Addendum
Effect Change Control Awards Not Assumed Effect Transfer
Effective Date Effective Expiration Date
Effectiveness Deadline Effectiveness Period
Efinitions Efits Change Control
Egal Onstruction Election Notice
Electrical Connection Consumption Eligibility Participation
Eligible Market Eligible Participant
Employee Employee Benefits Perquisites
Employee Stock Purchase Plan Employees
Employment Commencement Incentive Plan Employment Status
Enclosure Concealment Encountering Delay Enrolling Patients Clinical Trial Sns-595 Non-small
Encumbrances Eneral Rovisions
Entire Agreement Entry Material Definitive Agreement
Environment Environmental Laws
Equipment Financing Debt Facility Equity Compensation Committee
Equity Compensation Plan Information Equity Incentive Award Plan
Eric Bjerkholt Establishment Corporate Individual Objectives
Estimates Evaluation Date
Evaluation Disclosure Controls Procedures Even Receive Regulatory Approval Market Product Candidates Not
Even Receive Regulatory Approval Sell Voreloxin Market Not Event
Evidence Grant Exact Name Registrant Specified Charter
Exchange Act Excise Tax
Excluded Claims Excluded Securities
Exclusions Exclusive Remedy
Executive Chairman Chief Officer Executive Chairman Chief Officer Other Neos
Executive Compensation Executive Compensation Components
Executive Sessions Executive Severance Benefits Agreement
Executive Severance Benefits Agreements Exercise
Exercise Period Exercise Price
Exercise Purchase Price Exercise Shares
Exercise Termination Employment Service Exhibits
Existing Lease Base Rent Abatement Existing Tenancy
Expansion Premises Expansion Rights
Expect Expand Clinical Development Capabilities Difficulties Hiring Retaining Expect Expand Clinical Development Marketing Capabilities Difficulties Hiring
Expect Significantly Expand Clinical Research Development Marketing Capabilities Expenses
Expiration Date Extension Options
Facilities Located Near Known Earthquake Fault Zones Occurrence Facsimile Signatures
Fail Continue Comply Listing Requirements Nasdaq Global Market Fail Enter New Strategic Collaborations Reduce Scope Delay
Fail Maintain Existing Enter New Strategic Collaborations Reduce Failure Enroll Patients Clinical Trials Cause Delays Developing
Failure Exercise Failure Obtain Regulatory Approval Foreign Jurisdictions Prevent Marketing
Fair Market Value Fair Value Awards
Fair Value Measurements Fast Track Designation
Fda Fee
Fees Independent Registered Public Accounting Firm 2006 2005 Filing Deadline
Financial Highlights Financial Statements Exhibits
Financing Finra
Fix Alter Powers Preferences Rights Restrictions Other Matters Foreign Governments Often Impose Strict Price Controls Adversely
Foreign Participants Foreign Regulation
Forfeiture Form 10-k
Form Payment Former Name Address Changed Since Last Report
Forward-looking Statements Fractional Shares
Fragment-based Drug Discovery Approach Fundamental Transaction
Fundamental Transactions Further Actions
General General Administrative Expense
General Provisions General Purpose
General Release General Release Not Extend Claims Creditor Know Suspect
General Rights Generally Applicable Sunesis Lfa-1 Know-how
Generator License Global Credit Financial Market Conditions Negatively Impact Value
Good Reason Governing Law
Governing Law Venue Government Other Regulations
Government Regulation Governmental Authority
Grant Date Grant Fellowship Revenue
Grant Restricted Stock Grant Stock Appreciation Rights
Grants Plan-based Awards Table 2007 Graphic Floor Plan
Guarantees Indemnification Hazardous Materials
Hazardous Waste Headings
Health Health Benefits
Health Club Fees High Risk Drug Discovery Development Activities Halted Significantly
High Risk Drug Discovery Development Activities Significantly Delayed Highlights
Holder Holders
Homer Pearce Phd Householding Proxy Materials
Identification Audit Committee Financial Expert Identification Directors
Identification Executive Officers Ight Nterpret Lan Mendment Ermination
Ime Anner Ayments Imitations Ayments
Improvement Allowance In- License Agreement Dainippon Sumitomo Pharma Ltd
In-bound License Agreements Incentive Stock Option
Income Taxes Incur Significant Costs Complying Environmental Laws Regulations Failure
Incurred Losses Since Inception Anticipate Continue Incur Foreseeable Indemnification
Indemnification Directors Officers Indemnification Sarcode
Indemnification Sunesis Indemnified Party
Indemnifying Party Independence Members Board Directors
Independent Contractors Independent Director
Independent Registered Public Accountants Indicated Recurring Operating Losses Independent Registered Public Accounting Firm
Independent Stock Appreciation Rights Index
Index Financial Statements Information Regarding Committees Board Directors
Initial Closing Units Initial Public Offering
Initial Public Offering Ipo Initial Registration Statement
Insufficient Funds Insurance Indemnification
Intellectual Property Interest Expense
Interest Income Interest Income Expense
Internal Programs Internal Research Programs
Internal Revenue Code 162 Interpretation
Investor Rights Agreement Investors
Involuntary Termination Without Cause Irc
Irrevocable Transfer Agent Instructions Issuable Hereunder Shall Proportionately Increased Case Subdivision Warrant
Issuance New Warrants Issuance Restrictions
Issuer Filing Issuer Purchases Equity Securities
Ist Nvestors James Wells Phd
James Young Phd Johnson Pharmaceutical Research Development Llc
Johnson Prd Research Development Commercialization Collaboration Johnson Prd-research Development Commercialization Collaboration
Jonathan Leff Kashiwa Fudosan America Inc
Know-how Laims Nquiries Ppeals
Landlords Work Landlords Work Improvement Allowance
Landscaping Late Fee
Lead Purchasers Lease Payment Amounts
Lease Premises Legal Fees
Legal Proceedings Letter Agreement
Lfa-1 Lfa-1 Antagonist
Lfa-1 Compound Lfa-1 Confidential Information
Lfa-1 Legal Records Lfa-1 Program
Lfa-1 Records Liability
License Agreement License Agreements
Lien Life Disability Insurance
Ligibility Enefits Limitation Liability
Limitations Applicable Persons Limitations Effectiveness Controls
Limitations Liability Indemnification Limits Transfer
Liquidity Capital Resources Location Generator Tank
Long-lived Assets Long-term Equity-based Incentive Awards
Loss Per Share Losses
Lost Stolen Mutilated Destroyed Warrant Majority Investors
Majority Purchaser Unit Closing Notice Majority Purchasers
Managements Report Internal Control Over Financial Reporting Manufacturing Raw Materials
Market Registrants Common Equity Related Stockholder Matters Issuer Master Landlord Consent
Master Lease Agreements Material Adverse Effect
Material Changes Procedures Recommending Directors Material Contract
Matthew Fust Mechanics Conversion
Medical Benefits Arrangement James Young Phd Medical Insurance
Meetings Board Directors Merck Anti-viral License Research Collaboration
Merck Bace Research Development Commercialization Collaboration Merck Inc
Merck-anti-viral Inhibitors Merck-anti-viral License Research Collaboration
Merck-bace Inhibitors Merck-bace Research Development Commercialization Collaboration
Milestones Miscellaneous Provisions
Mitigation Mix Pay
Mixed Original Records Monday Oral Presentation
Mount Ayments Mplied Mployment Ontract
Multiple Myeloma Research Consortium Mutual Representations Warranties
Name Nea
Need Raise Additional Capital Net Exercise
Never Paid Dividends Capital Stock Not Anticipate Paying New Drug Application
New Drug Applications New Registration Statement
Noises Odors Other Matters Nominating Corporate Governance Committee
Nominations Process Non-disparagement
Non-disturbance Quiet Enjoyment Non-employee Director
Non-publication Non-qualified Deferred Compensation 2006
Non-qualified Stock Option Nondisclosure Terms Press Release
Not Applicable Not Sufficient Funding Distribute Capital Common Stockholders Continue
Notes Receivable Officers Notes Receivable Officers Employees
Notice Notice Annual Meeting Stockholders Held 2007
Notice Annual Meeting Stockholders Held 2008 Notice Bona Fide Offer
Notice Defects Notice8221
Notices Notices Etc
Notices Record Date Notices Record Date Certain Other Events
Now Therefore Ntroduction
Number 000-51531 Obligations Master Lease Agreement
Occupancy Work Off-balance Sheet Arrangements
Office Lease Oncology Therapeutics Network Joint Venture
Ongoing Collaborations Operating Capital Expenditure Requirements
Operating Expenses Property Taxes Option
Option Acceleration Option Agreement
Option Exercises Stock Vested 2007 Optional Conversion
Optionee Order Received Counted
Organization Original Issue Date
Original Issue Price Other Accrued Liabilities
Other Business Other Elements Compensation Perquisites
Other Event Occurs Involves Subtenant Premises Constitute Default Other Events
Other Income Expense Net Other Information
Other Investor Rights Other Kinase Inhibitors Programs
Other Matters Annual Meeting Other Neos
Other Oncology Kinase Programs Other Programs
Other Regulatory Requirements Other Result Change Control Executives Direct Reporting Relationship
Other Rights Other Terminations
Other Types Awards Outstanding Awards Certain Mergers
Outstanding Awards Other Changes Outstanding Equity Awards Table 2007
Outstanding Stock Awards Ovarian Cancer
Overview Ownership Capital Stock Highly Concentrated Interests Conflict Existing
Ownership Common Stock Highly Concentrated Interests Conflict Existing Ownership Sunesis Securities
Parent Entity Parking
Parking Access Signage Part
Part Other Information Participant
Partnered Programs Party
Patent Payment
Payment Limitations Exercise Payment Taxes
Payment Taxes Expenses Peer Group
Performance Criteria Performance Goals
Performance Graph Performance Period
Performance Share Performance Share Awards
Performance-based Award Permits
Permitted Encumbrances Permitted Liens
Permitted Transferee Person
Phase Study Single Agent Voreloxin Newly Diagnosed Elderly Phase Study Single Agent Voreloxin Women Platinum-resistant Ovarian
Phase Study Voreloxin Combination Cytarabine Relapsed Refractory Aml Phase Subsequent Clinical Trials Lead Product Candidates Sns-595
Plan Position Duties
Possession Surrender Premises Post-termination Compensation
Potential Payments Termination Change Control Pre-approval Policies
Preclinical Testing Inds Preferred Stock
Premises Press Release
Price Cash Other Consideration Number Shares Fully Paid Price Common Stock Continue Volatile Value Investment Decline
Principal Accountant Fees Services Principal Amount Original
Principal Trading Market Principles Consolidation
Prior Agreement Prior Benefits Agreement
Private Placement Private Placement Accounting
Pro Forma Information Sfas 123 Periods Prior 2006 Pro Rata Amount
Pro Rata Amounts Pro Rata Share
Proceeding Proceeds
Proceeds Registered Securities Product
Professional Requirements Program Bonus Targets
Program Objectives Programs
Promissory Notes Properties
Property Equipment Proposal Election Nominees Board Directors
Proprietary Fragment-based Drug Discovery Approaches Experimental Not Discover Proprietary Information Obligations
Proprietary Rights Not Adequately Protect Technologies Product Candidates Proprietary Rights Not Adequately Protect Voreloxin Future Product
Proprietary Tethering Drug Discovery Approach Experimental Not Discover Prospectus
Provided Further Provided However
Provisions Applicable Awards Provisions Charter Documents Delaware Law Delay Prevent Acquisition
Proxy Solicited Behalf Board Directors Proxy Statement
Proxy Voted Directed Contrary Direction Indicated Election Director Public Offering
Public Trading Date Purchase Agreement
Purchaser Deliverables Purchaser Party
Purchaser Put Notice Purchaser Unit Closing Notice
Purchasers Purchases Common Stock
Purpose Pursuant 302 Sarbanes-oxley Act 2002
Pursuant 906 Sarbanes-oxley Act 2002 Qualified Performance-based Compensation
Quantitative Qualitative Disclosures Market Risk Quorum Voting Requirements
Raf Kinase Inhibitors Program Recent Accounting Pronouncements
Recent Highlights Recitals
Regents University California Registrable Securities
Registrants Telephone Number Including Area Code Registration
Registration Statement Registration Statements
Regulation Regulatory Approval Process Expensive Time Consuming Uncertain Prevent
Reissuance Series Preferred Related Party Transactions
Relationship Other Benefits Release
Release Group Termination Release Individual Termination
Release Prior Payment Release Prior Payment Benefits
Released Claims Released Parties
Rely Parties Conduct Clinical Trials Not Successfully Carry Rely Parties Conduct Clinical Trials Sns-595 Sns-032 Sns-314
Rely Parties Manufacture Product Candidates Including Sns-595 Sns-032 Rely Parties Manufacture Voreloxin Drug Product Active Pharmaceutical
Rely Party Manufacture Product Candidates Including Sns-595 Sns-032 Remainder Registration Statements
Removal Restoration Reorganizations Mergers Consolidations
Report Audit Committee Board Directors Report Independent Registered Public Accounting Firm
Reporting Comprehensive Income Representations
Representations Warranties Represents Warrants Holder Warrant Follows Representations Warranties Sarcode
Representations Warranties Sunesis Require Substantial Additional Funding Not Available Acceptable Terms
Required Approvals Requisite Holders
Resale Registration Statement Research Development
Research Development Expense Reservation Stock Issuable Conversion
Reserved Shares Restricted Stock
Restricted Stock Awards Restricted Stock Unit
Restricted Stock Units Restrictions
Restructuring Restructuring Charges
Restructuring Plan Results Annual Meeting
Results Operations Results Operations Financial Condition
Results Preclinical Studies Clinical Trials Not Satisfy Requirements Retirement Savings
Revenue Revenue Recognition
Revenues Reverse Stock Split Conversion Preferred Connection Ipo
Reverse Stock Split Initial Public Offering Revocability Proxies
Right Convert Warrant Stock Net Issuance Right Employment Services
Rights Awards Risk Factors
Risk Securities Class Action Litigation Risks Related Common Stock
Risks Related Industry Role Authority Compensation Committee Board
Roof Antenna License Rule 144
Rule 415 Rule 424
Rules Russell Hirsch Phd
Safe Harbor Statement Sales Common Stock
Sar Sarcode Corporation
Sarcode Inc Saturday Poster Presentation
Schedule 14a Scope Right
Sec Guidance Sec Reports
Secretary8217s Certificate Securities
Securities Act Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Registered Pursuant Act
Security Deposit Security Ownership Certain Beneficial Owners Management Related Stockholder
See Selected Quarterly Financial Data
Sell Shares Common Stock Future Financings Stockholders Experience Selling Stockholder Questionnaire
Separate Vote Series Preferred Series Preferred
Series Preferred Conversion Price Series Preferred Conversion Rate
Series Preferred Stock Severability
Severance Severance Benefits
Severance Change Control Benefits Share-based Payment
Share-based Payments Shares
Shares Registered Name Bank Broker Other Nominee Shares Registered Name Stockholder
Shares Subject Plan Short Sales
Signature Signature Page Follows
Signatures Significant Portion Outstanding Common Stock Sold Market Near
Significant Risks Uncertainties Sns-032 Program
Sns-314 Program Sns-595 Program
Solicitation Source Sunesis Pharmaceuticals Inc
Sources Liquidity South San Francisco 2005
South San Francisco 2006 South San Francisco Calif 2009
Special Mandatory Conversion Special Regarding Forward-looking Statements
Special Registration Statement Specified Employee
Stand-alone Tandem Awards Stephen Fodor Phd
Steven Goldby Stock
Stock Appreciation Rights Stock Awards
Stock Certificates Stock Compensation Options Granted Prior Ipo
Stock Distributed Stock Option Acceleration
Stock Option Grants Awards Stock Option Plans
Stock Options Stock Payment
Stock Payments Stock Plan 2001
Stock-based Compensation Stock-based Compensation Options Granted Prior Ipo
Stock-based Payments Stockholder Approval
Stockholder Approval Date Stockholder Approval Not Required
Stockholder Communications Board Directors Stockholder Proposals Inclusion 2007 Proxy Statement
Stockholder Proposals Inclusion 2009 Proxy Statement Stockholder Proposals Presentation 2008 Annual Meeting
Stockholders Equity Stockholders Rights
Stockholders Sharing Same Address Stockholders8217 Equity
Stockholders8217 Meeting Strategic Collaborations
Strict Construction Subject Costly Claims Related Clinical Trials Not Able
Subject Damages Resulting Claims Employees Wrongfully Used Disclosed Subject Numerous Risks Connection 404 Sarbanes-oxley Act
Sublandlord Shall Also Other Rights Privileges Options Reservations Sublease Assignment
Sublease Commencement Sublease Term
Submission Matters Vote Security Holders Subsequent Events
Subsidiaries Registrant Subsidiary
Subtenant Fails Pay Other Amount Due Applicable Date Subtenant Improvements
Subtenant Shall Not Make Changes Alterations Additions Premises Successor Entity
Successors Successors Assigns
Sued Infringing Intellectual Property Rights Parties Litigation Costly Suite 400 Base Rent Abatement
Suite 400 Termination Right Suite 402
Suites Summary Compensation Table 2007 2006
Sunesis Sunesis Lfa-1 Intellectual Property
Sunesis Lfa-1 Know-how Sunesis Lfa-1 Patents
Sunesis Pharmaceuticals Sunesis Pharmaceuticals Appoints Helen Kim Board Directors
Sunesis Pharmaceuticals Inc Sunesis Pharmaceuticals Inc 341 Oyster Point Boulevard South
Sunesis Pharmaceuticals Receives Nasdaq Notification Sunesis Reports Financial Results 2009
Superior Proposal Survival
Suspension Certificate Suspension Period
Table Contents Tax Accounting Considerations
Taxes Tenants Supplementary Improvement Allowance
Tenants Termination Right Term
Term License Termination
Termination Benefits Termination License Agreement
Termination Service Terms Conditions
Ther Lan Nformation Time Conditions Exercise
Timing Cash Payments Program Title Class
Titles Headings Total Share-based Compensation Expense
Total Stock-based Compensation Expense Trading
Trading Market Transaction Documents
Transaction Stockholder Approval Matters Transfer Agent
Transfer Warrant Transferred Assets
Translation Premises Treatment Confidential Information
Unable Raise Additional Capital Near Term Not Able Understand Agree Completely Terms Set Forth Sunesis Pharmaceuticals
Unfunded Status Awards Unit Closing
Unit Closing Date Unit Closing Notice
Unit Closing Subscription Amount Unit Purchase Price
Unit Shares Units
University California San Francisco Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds Unrestricted Securities
Update Clinical Programs Update Pipeline Programs
Violations Voreloxin
Voreloxin Abstracts Accepted Presentation Ash Vote Important Accordingly Please Complete Sign Return Accompanying
Vote Received Prior Annual Meeting 2008 Voting Person Mail
Voting Procedures Voting Quorum Abstentions Requirements
Voting Rights Outstanding Shares Voting Securities
Waiver Waiver Amendment
Waiver Claims Indemnity Waiver Subrogation
Warrant Exercise Cap Warrant Ratio
Warrant Shares Warrants
Whereas Whole Agreement
Withholding Witness Whereof
Work Generator Area Workforce Reduction Announced 2007 Future Expense Reductions Adverse
Workforce Reductions 2007 2008 2009 Future Expense Adverse Xecution
Xhibit 991 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki